4.48

2.28% 0.10

After Hours: 4.48

Oramed Pharmaceuticals Inc (ORMP)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Oramed Pharmaceuticals Inc stock is traded at $4.48, with a volume of 156.77K. It is up +2.28% in the last 24 hours and up +12.00% over the past month. Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.

Previous Close:

$4.38

Open:

$4.3

24h Volume:

156.77K

Relative Volume:

0.55

Market Cap:

$186.36M

Revenue:

$2.00M

Net Income/Loss:

$109.16M

P/E Ratio:

1.7341

EPS:

2.5835

Net Cash Flow:

$-9.11M

1W Performance:

+4.19%

1M Performance:

+12.00%

6M Performance:

+37.85%

1Y Performance:

+111.32%

1-Day Range:

$4.30

$4.53

1-Week Range:

$4.16

$4.53

52-Week Range:

$1.975

$5.19

Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile

Name

Oramed Pharmaceuticals Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

646-844-1164

Address

1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY

Employee

Twitter

@OramedPharma

Next Earnings Date

2026-08-13

Latest SEC Filings

ORMP's Discussions on Twitter

Compare ORMP vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ORMP Oramed Pharmaceuticals Inc	4.48	177.62M	2.00M	109.16M	-9.11M	2.5835
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-12-23	Downgrade	Canaccord Genuity	Buy → Hold
Feb-18-22	Initiated	Cantor Fitzgerald	Overweight
Apr-20-21	Initiated	Canaccord Genuity	Buy
Feb-09-21	Initiated	National Securities	Buy
Dec-03-20	Initiated	Alliance Global Partners	Buy
Mar-11-20	Initiated	Aegis Capital	Buy
Sep-11-19	Initiated	Ladenburg Thalmann	Buy
Dec-11-17	Resumed	B. Riley FBR, Inc.	Buy
May-26-16	Reiterated	FBR Capital	Outperform
Dec-01-15	Reiterated	H.C. Wainwright	Buy
Nov-19-15	Initiated	FBR Capital	Outperform
Apr-13-15	Resumed	MLV & Co	Buy
Jan-30-14	Reiterated	Aegis Capital	Buy
Jan-08-14	Reiterated	Aegis Capital	Buy
Jan-08-14	Initiated	MLV & Co	Buy
Dec-03-13	Initiated	Aegis Capital	Buy

View All

Oramed Pharmaceuticals Inc Stock (ORMP) Latest News

02:01 AM

Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by Wall Street Zen to Buy Rating - MarketBeat

02:01 AM

Aug 14, 2026

Aquamarine Financial (ORMP) discloses 6.04% Oramed ownership in 13G/A - Stock Titan

Aug 14, 2026

Aug 13, 2026

Oramed Pharmaceuticals Inc (NASDAQ: ORMP) Share Price, ORMP Stock News, ORMP Share Price & Updates - Kalkine

Aug 13, 2026

Aug 12, 2026

MSN Money - MSN

Aug 12, 2026

Aug 10, 2026

Oramed Pharmaceuticals (NASDAQ:ORMP) Releases Quarterly Earnings Results - MarketBeat

Aug 10, 2026

Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a shareEarnings Preview - TradingView

Aug 10, 2026

Oramed: Q2 Earnings Snapshot - marketscreener.com

Aug 10, 2026

ORAMED PHARMACEUTICALS INC. 2Q 2026: Revenue $0 Net income $78.16M, EPS $1.84— 10-Q Summary - TradingView

Aug 10, 2026

Oramed Pharmaceuticals (NASDAQ: ORMP) pivots to investment model with $116M profit - Stock Titan

Aug 10, 2026

Aug 07, 2026